The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.
Phase:
PHASE1
Details
Lead Sponsor:
Jeffrey Statland
Collaborators:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) University of Rochester University of Washington